NSE / BSEHealthcare
β‚Ή492.15+16.60+3.49%
P/E302.0Mkt Capβ‚Ή15.85 K CrEV/EBITDA62.8

Dr. Agarwal's Health Care Limited

P/E302.0Mkt Capβ‚Ή15.85 K CrEV/EBITDA62.8
Company Profile

Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 10.51% over 1Y
Monthly Returns

Historically, Sep has averaged the highest return (+17.2%); Jan the lowest (-14.4%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-14.4%Negative MonthJan 2026: -14.41%+3.7%Positive MonthFeb 2026: +3.69%-10.0%Negative MonthMar 2026: -10.03%+9.4%Positive MonthApr 2026: +9.41%+7.9%Positive MonthMay 2026: +7.87%-0.0%Neutral MonthJun 2026: -0.03%+2.7%*Positive MonthJul 2026: +2.71%β€”β€”β€”β€”β€”
2025β€”β€”+11.1%Positive MonthMar 2025: +11.13%-18.1%Negative MonthApr 2025: -18.15%-7.4%Negative MonthMay 2025: -7.38%+19.5%Positive MonthJun 2025: +19.48%+13.1%Positive MonthJul 2025: +13.08%-5.4%Negative MonthAug 2025: -5.39%+17.2%Positive MonthSep 2025: +17.24%+0.3%Neutral MonthOct 2025: +0.34%+4.9%Positive MonthNov 2025: +4.88%-4.8%Negative MonthDec 2025: -4.80%
AvgΒ±SD-14.4%Β±0.0%+3.7%Β±0.0%+0.5%Β±10.6%-4.4%Β±13.8%+0.2%Β±7.6%+9.7%Β±9.8%+7.9%Β±5.2%-5.4%Β±0.0%+17.2%Β±0.0%+0.3%Β±0.0%+4.9%Β±0.0%-4.8%Β±0.0%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 2 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 0.967x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή1.04 K Crβ–² 25.0%
EBITDA Growthβ€”
Net Profitβ‚Ή22.00 Crβ–Ό 8.3%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 119.2%
Revenue CAGR 5Y27.5%
EBITDA CAGR 5Y36.6%
Net Profit CAGR 5Y0.0%
NP Growth 1Y-8.3%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή1.04 K Crβ€”β‚Ή22.00 Crβ€”β€”1.1%25.0%-8.3%
Mar 2024β‚Ή835.00 Crβ€”β‚Ή24.00 Crβ€”β€”2.0%39.6%-25.0%
Mar 2023β‚Ή598.00 Crβ€”β‚Ή32.00 Crβ€”β€”5.7%65.2%-3300.0%
Mar 2022β‚Ή362.00 Crβ€”β‚Ή-1.00β€”β€”-0.5%56.0%-98.1%
Mar 2021β‚Ή232.00 Crβ€”β‚Ή-54.00β€”β€”-26.9%-6.5%50.0%
Mar 2020β‚Ή248.00 Crβ€”β‚Ή-36.00β€”β€”-14.1%22.8%80.0%
Mar 2019β‚Ή202.00 Crβ€”β‚Ή-20.00β€”β€”-6.7%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales2022482323625988351,0441,160
Total Expenses186202199275436611795886
EBIT / Operating Profit16463386162224249274
OPM %8%19%14%24%27%27%24%24%
Other Income59410-12384052
Finance Costs2042343864889481
Depreciation & Amortisation2149555992129156174
Profit Before Tax-20-36-52-1-6453971
Tax %0%0%4%55%-641%47%43%-
Net Profit / PAT-20-36-54-132242249
EPS (β‚Ή)------0.691.56
Dividend Payout %0%0%0%0%0%0%0%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Dr. Agarwal's Health Care Limitedthis co.β‚Ή15.85 K Crβ‚Ή1.04 K Cr302.008.0962.8325.0%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Dr. Agarwal's Health Care Limited and the metrics that matter.

Browse the full Equiscale Academy